Handbook of Clinical medicine

or ketonuria). One option is 2-hourly ultra fast-acting insulin (eg 6–8U) preceded by a fi ngerprick glucose check. • Admit if vomiting, dehydrated, ketotic (p832), a child, or pregnant. Insulin pumps (continous subcutaneous insulin) Consider when attempts to reach HbA1C with multiple daily injections have resulted in disabling hypoglycaemia or person has been unable to achieve target HbA1C despite careful management. Glucagon-like peptide (GLP) analogues (exenatide, liraglutide) Work as incretin mimetics. Incretins are gut peptides that work by augm ent ing insulin release. Given by subcutaneous injection. Patients must have BMI >35 and specifi c psychological or other medical problems associated with obesity, or have a BMI lower than 35 kg/m2, and for whom insulin therapy would have signifi cant occupational implications, or weight loss would benefi t other signifi cant obesity- related comorbidities. To continue a GLP 1 mimetic, a person should have a bene- fi cial metabolic response (a reduction of HbA1C by at least 11mmol/mol) and a weight loss of at least 3% of initial body weight in 6 months. __OOHHCCMM__1100ee..iinnddbb 220099 0022//0055//22001177 1199::0077 ygolonircodnE 210 Complications of established diabetes Prospective studies show that good control of hyperglycaemia is key to preventi ng microvascular complications in type
